Background/Objectives: Bladder cancer is a significant clinical problem with approximately 500,000 new cases worldwide annually. In approximately 25% of cases, disease is diagnosed at a stage of invasion of the muscle layer of the bladder. The current standard approach in this disease is preoperative chemotherapy followed by radical cystectomy. Dose-dense MVAC (ddMVAC), a two-day chemotherapy regimen, is the reference treatment protocol in this setting. The presented study evaluated the effectiveness and safety of accelerated MVAC (aMVAC) chemotherapy—a one-day regimen given before the resection of the bladder due to muscle-invasive disease.Methods: A retrospective analysis included 119 consecutive patients diagnosed with urothelial muscle-invasive bladder cancer (MIBC) who underwent preoperative chemotherapy with the aMVAC regimen. The planned treatment included 4–6 cycles of preoperative chemotherapy. The analysis of the degree of histopathological response to treatment was based on the three-grade TRG (tumor regression grade) classification.Results: A complete pathological response (TRG1) was observed in 44 patients (36.7%), and a major pathologic response (
背景/目的：膀胱癌是一个重要的临床问题，全球每年约有50万新发病例。约25%的病例在诊断时已进展至膀胱肌层浸润阶段。目前该疾病的标准治疗方案为术前化疗后进行根治性膀胱切除术。剂量密集型MVAC方案（ddMVAC）作为为期两天的化疗方案，是该治疗情境下的标准参考方案。本研究旨在评估加速型MVAC方案（aMVAC）——一种为期一天的化疗方案，在肌层浸润性膀胱癌患者膀胱切除术前应用的有效性与安全性。
方法：本研究对119例连续收治的尿路上皮肌层浸润性膀胱癌患者进行回顾性分析，所有患者均接受术前aMVAC方案化疗。计划治疗方案包括4-6个周期的术前化疗。采用三级肿瘤退缩分级系统对组织病理学治疗反应程度进行评估。
结果：44例患者（36.7%）达到完全病理缓解（TRG1），58例患者（48.7%）实现主要病理缓解（ 摘要翻译：
原文链接：
肿瘤(癌症)患者之家